Florence Healthcare has released its annual State of Clinical Trial Technology Industry Report. More than 230 clinical operations professionals across the drug development lifecycle participated in this year's report, revealing how they plan to invest in technology over the next three years.
Key findings from the survey conducted online in late November and early December include:
- 47% of sites and 36% of sponsors indicated they increased their 2020 technology budgets to reduce disruptions from COVID.
- 65% of sites intend to have an electronic investigator site file (eISF) in place by the end of 2020, and 47% expect to use eConsent.
- 90% of sites state that increasing their chances of being selected by a sponsor for a study is one of their primary reasons for investing in technology.
- 80% of sites and 83% of sponsors anticipate that most or all of their monitoring visits will be conducted remotely by 2023.
For more of the report’s findings, click here.